Backgrounds/Aims: During the acute phase response, cytokines induce marked alterations in lipid metabolism including an increase in serum triglyceride levels and a decrease in hepatic fatty acid oxidation, in bile acid synthesis, and in high-density lipoprotein levels. Methods: Peroxisome proliferator-activated receptors (PPARs: PPARα, β/δ, and γ) regulate fatty acid metabolism, glucose homeostasis, cell proliferation, differentiation and inflammation. Proinflammatory profiles including tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) are the important pathological factors in inflammatory responses during the pathological progression of the acute phase response. Lipopolysaccarides (LPS) induced the expression of TNF-α, IL-1β, and IL-6. LPS-induced inflammation decrease the expression of peroxisome proliferator-activated receptor α (PPARα), PPARβ/δ, PPARγ, and coactivators PPARγ coactivator 1 α (PGC-1α), PGC-1β messenger RNA (mRNA) in the liver of Balb/c mouse. In addition, LPS-induced inflammation diminishes the protein level of PPARα, PPARβ/δ, and PPARγ. Proinflammatory cytokines including TNFα, IL-1β, and IL-6 are the principal reducer of PPARs. However, the knockout mouse model against TNFα and IL-6 does not block decrease of PPARs in serum and liver. The mice were pretreated with fenofibrate at 100 mg/kg for 2 days. Results: These treatment protocols increased the amount of PPARs mRNA in the liver. Fenofibrate inhibited LPS-induced TNF-α, IL-1β, and IL-6 production in the serum and liver. Similar results were obtained when human hepatoma HepG2 cells exposed to LPS were co-incubated with fenofibrate. LPS-treated HepG2 cells decreased expression of IκB. Moreover, activation of PPARs abrogated LPS-induced degradation of IκB, thus suppressing LPS-induced NF-κB activities. Conclusions: Therefore, fenofibrate decreases the expression and secretion of TNF-α, IL-1β, and IL-6 via the NF-κB signaling pathway, thus serving as therapeutic targets to attenuate inflammation that is involved in hepatic pathological progression. (Korean J Hepatobiliary Pancreat Surg 2013;17:89-108)
INTRODUCTION
The acute phase response (APR) is a generalized response of the organism to multiple disturbances of its physiological homeostasis. Inflammatory processes are the main causes for the initiation of these defense mechanisms. 1 As part of systemic inflammatory reactions, interleukin 6 (IL- 6) regulates APR genes in liver cells including C-reactive protein (CRP), fibrinogen, serum amyloid A (SAA), α2-macroglobulin, and albumin. 2 Elevated levels of IL-6 and liver APR genes that are a reflection of the inflammatory state have been reported in patients with acute coronary syndrome. 3 IL-6 actions are mediated by a specific cell surface IL-6 receptor (IL-6R), an 80-kDa glycoprotein (gp80), and a signal transducing molecule, glycoprotein gp130, which is also the signaling molecule for various IL-6 family cytokines. 4 IL-6 binds to its cognate receptor, and IL-6/IL-6R forms a complex with a gp130 homodimer.
Ligand-induced oligomerization of receptor subunits leads to activation and phosphorylation of a signal transducer and activator of transcription 3 (STAT3) and of linker proteins, which propagate the signal to other pathways and cause activation of immediate early response genes, such as c-jun.
belong to the superfamily of nuclear receptors. 8 PPARs are activated by natural ligands such as fatty acids, eicosanoids, and oxidized fatty acids. 9 Of the 3 PPAR family members, PPAR-α, PPAR-β/δ, and PPAR-γ, PPAR-α is the target of the lipid-lowering fibrates. 9 PPARs regulate gene expression by forming heterodimers with the retinoid X receptor (RXR) and binding to specific DNA sequences located in the promoter region of target genes, termed PPAR response elements (PPRE transactivation).
PPREs consist of a direct repeat (DR) of a hexameric AGGTCA recognition site separated by 1 (DR-1) or 2 nucleotides (DR-2). 10 A physiological role for PPAR-α is to control FA oxidation in response to fasting by inducing ketone body formation 11 and high-fat-feeding. 12 PPAR-α also plays a major role in lipid homeostasis by controlling key genes encoding enzymes and apolipoproteins involved in lipoprotein metabolism. 13 Furthermore, PPAR-α displays antiinflammatory activities and controls the inflammatory response in the vascular wall. 14 The control of inflammatory pathways by PPARα occurs mainly via repression of target genes caused by negative interference in a DNA-binding-independent manner (transrepression). 14 It is well-established that serum concentrations of hepatic inflammatory response genes (eg, fibrinogen, CRP, SAA) are elevated in patients with coronary artery disease (CAD), and several of the genes, including fibrinogen and CRP, are considered as risk markers.
14 PPARα seems to decrease inflammation, mainly through direct interaction with NFκB, causing inhibition of its signaling pathway or reducing the activated levels of NFκB and subsequent inflammation. In fact, PPARα was reported to protect the liver from obesity-induced inflammation after feeding with a high-fat diet (HFD) for 6 months. 15 Furthermore, PPARα was implicated in the attenuation of oxidative stress in alcoholic liver disease when treated with polyenephosphatidylcholine through downregulation of ROS generating enzymes such as ethanol-inducible cytochrome P450 2E1 (CYP2E1), acyl-CoA oxidase, and NADPH oxidase.
PPARγ, a nuclear transcription factor, regulates lipid metabolism and the inflammation response, and maintains the quiescent phenotype of hepatic stellate cells. 16, 17 PPARγ knockout causes hepatic insulin resistance and increases the plasma free fatty acids level. 16 Dysfunction of PPARγ is related to the inflammatory and pro-fibrogenic actions in the liver, 17 inferring that PPARγ may play a major role in the pathogenesis of non-alcoholic steatohepatitis. 
METHODS

Chemicals and supplies
The lipopolysaccharide (LPS) (Escherichia coli 055:B5 clone), fenofibrate, was purchased from Sigma (St. Louis, Mo, USA). Plastic culture wares were purchased from 
Culture and treatment of HepG2 cells
Measurement of proinflammatory cytokines
To quantify the secretion of proinflammatory cytokines from LPS-treated Balb/c, TNF-α knockout, and IL-6 knockout mice, whole blood was isolated from the mice before sacrifice, incubated at 4 o C for 16 h, and centrifuged at 4,000 rpm for 20 min. Thereafter, the level of proinflammatory cytokines was determined by ELISA according to the manufacturer's instructions.
Assay for messenger RNA expression by reverse transcriptase-polymerase chain reaction (RT-PCR)
After extracting total RNA from the liver using TRIzol, the complementary DNA (cDNA) was synthesized using reverse transcriptase. RNA (2 μg) and oli- Measurement of hepatic messenger RNA levels by quantitative real-time polymerase chain reaction (QRT-PCR)
RNA was extracted using TRIzol and cDNA was synthesized using Superscript III. Semiquantitative real-time PCR analysis using Fast SYBR Green Master Mix (AB) was performed using a Step One Plus (AB). Primers are listed in Table 2 . 
Preparation of cell extracts
Briefly, HepG2 cells were disrupted in a sucrose- Western blot analysis 
Hematoxylin and eosin staining
After the experiment, the liver was fixed in 4% formaldehyde for 16 h at 4 o C and embedded in paraffin.
Sections were stained with hematoxylin and eosin.
Statistic analysis
Each experiment was performed at least 3 times in- 
RESULTS
Injection with LPS increased leukocyte recruitment into liver and liver injury
At first, the mice were weighed after LPS injection (Fig. 2) . (Fig. 6B ). In addition, LPS decreased . Expression level of PPARs, PGC1β, ACOX1, SREBP1α, SREBP1c, and SREBP2 mRNA was determined by qPCR (normalized to GAPDH). Balb/c mice were injected with LPS. Total RNA from the liver was isolated. Two micrograms of total RNA was reverse transcribed to cDNA. PPARs (A), PGC1β and ACOX1 (B), SREBP1α, SREBP1c, and SREBP2 (C) mRNA expression was measured by real-time QPCR as described under "Methods". QPCR data were normalized using GAPDH mRNA as the invariant control for all experiments. Data (mean±SD) are expressed as a relative unit. (Fig. 9C) . In IL-6 KO mouse, LPS injection resulted in a marked increase of TNF-α secretion, which reached a peak level of 1749.417±10.053 pg/ml at 2 h, and then decreased in a time-dependent manner (Fig. 9D ).
In addition, LPS induced an increased release of IL-1β, which was observed as early as 2 h (120.3412±2.658 pg/ml) and reached a peak level of 290.9527±3.338 pg/ml at 4h, and then decreased in a time-dependent manner (Fig. 9E ). There were no secretions of TNF-α and IL-6
in TNF-α KO (Fig. 9A ) and IL-6 ( Fig. 9F ) KO mouse.
VCAM and ICAM were induced in the liver with LPS-injected TNF-α (Fig. 10A ) and IL-6 ( Liver from knockout mice injected with PBS or LPS were removed and embedded in paraffin, and then 4 μm sections were prepared. For immunohistochemistry studies, an immunohistochemistry kit was used, and all the procedures were performed according to the instructions of the manufacturer. The anti-TNF-α and anti-Tall like receptor (TLR) 4 were used. All results were representative of three separate experiments.
mice. An increase in the RT-PCR products of proinflammatory cytokine mRNAs was detected (Fig. 10B, D) . KO mouse (Fig. 12C) . Moreover, PGC1α and PGC1β mRNA levels of LPS-treated mice decreased in the liver of TNF-α and IL-6 KO mice (Fig. 12B, D) . Furthermore, LPS injection decreased the expression of PPARα protein in TNF-α and IL-6 knockout mice (Fig. 13A, B) .
Pretreatment with fenofibrate attenuated leukocyte recruitment and liver injury after LPS
To explore the role of PPARα activation on LPS-induced proinflammatory cytokines and inflammation-related PPARs gene expression in the liver, I pretreated the mice with a PPARα agonist, fenofibrate, as described in Fenofibrate inhibited LPS-induced elevation of pro-inflammatory cytokines in serum and liver of Balb/c, TNF-α KO, and IL-6 mice
To gain further insight into the mechanisms underlying the proinflammatory profile blockade by fenofibrate, I injected fenofibrate as described in 'Methods'. As shown in However, fenofibrate blocked degradation of IκBα and Fig. 12 . Expression level of PPARs, PGC1β, ACOX1, SREB-P1α, SREBP1c, and SREBP2 mRNA was determined by QP-CR (normalized to GAPDH) in the liver of KO mice. TNF-α (A, B) and IL-6 (C, D) KO mice were injected with LPS. Total RNA from liver was isolated. Two micrograms of total RNA was reverse transcribed to cDNA. PPARs (1), PGC1β and ACOX1 (2), SREBP1α, SREBP1c, and SREBP2 (3). mRNA expression was measured by real-time QPCR as described under "Methods." QPCR data were normalized using GAPDH mRNA as the invariant control for all experiments. Data (mean±SD) are expressed as a control level. proteins. However, treatment with fenofibrate blocked degradation of PGC1β and PMP70 proteins (Fig. 17B) .
Fenofibrate inhibited LPS-induced elevation of pro-inflammatory cytokines in HepG2
As shown in Fig. 18 , LPS increased the proinflammatory cytokines mRNA level including TNF-α, IL-1β, and IL-6 in the human hepatoma cell line, 19 . Effect of fenofibrate on PPARs mRNA level in the liver of Balb/c. Fenofibrate (100 mg/kg) or its vehicle (water containing 0.5% methylcellulose) were administered. After LPS injection, total RNA from the liver was isolated. Two micrograms of total RNA was reverse transcribed to cDNA. PPARs mRNA expression was measured by real-time QPCR as described under "Methods." QPCR data were normalized using GAPDH mRNA as the invariant control for all experiments. Data (mean±SD) are expressed as a relative unit.
HepG2. However, pretreatment with fenofibrate decreased the proinflammatory cytokines mRNA level (Fig. 18 ).
Pretreatment with fenofibrate elevated PPARs mRNA in patients with acute coronary syndrome and reflect the inflammatory state. 3 The expression levels of APPs are regulated by fibrates, 29 which act via a PPARα-dependent mechanism. 30 Hence, several acute phase response markers such as fibrinogen, CRP, SAA, α2-macroglobulin, and plasminogen are lowered after fenofibrate treatment in humans, whereas levels of albumin, a negative acute phase response protein, are raised.
Several studies have delineated the cellular and molecular mechanisms explaining the modulation of the hepatic inflammation response by PPARα activation (Fig. 21) . 
